Brand Taiwan Only

Coronavirus Mutants Pipeline

♦ Coronavirus Spike Mutants
Since emerging in 2019, SARS-CoV-2’s genome has proved to be relatively stable. However, the emergence of multiple new variants in late 2020 has caused concern over the efficacy of recently-developed countermeasures, including diagnostics, therapeutics and vaccines. Many mutations have occurred in the Spike protein and its receptor-binding domain (RBD), which plays a central role in pathogenesis and the induction of neutralising antibodies. To identify and investigate the effects of these mutations, extensive work is now underway.

Our Mutant Pipeline
To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of mutant Spike antigens. Expressed from our proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.

Spike Mutation Map
The map below shows all the Spike mutations we currently provide or are developing in relation to the original Wuhan-Hu-1 sequence: